PLEASANTON, Calif., Nov. 19 Thoratec Corporation(Nasdaq: THOR), a world leader in products to treat cardiovascular disease,today announced the appointment of healthcare executive Steven H. Collis toits board of directors, effective January 1, 2008. His appointment brings theThoratec board to nine directors.
Collis, who will join the board's compensation and option committee, isexecutive vice president of AmerisourceBergen Corporation, and president ofits Dallas-based AmerisourceBergen Specialty Group (ABSG). ABSG deliversspecialty pharmaceuticals and related services to physician offices, includingreimbursement consulting and physician education.
Collis joined AmerisourceBergen in 1994 as a general manager in ASDSpecialty Healthcare, and was named president of its Specialty Group in 1999.He was previously a principal and general manager of Sterling Medical, anational provider and distributor of medical disposable supplies, healthmanagement services and continuous quality management programs to the homecare market.
Born and educated in South Africa, Collis holds a Bachelor of Commercewith Honors degree from the University of the Witwatersrand in Johannesburg.He received his Charter Accountancy license, the South African equivalent of aCertified Public Accountant license.
"We are very excited to have someone with Steve's extensive and impressiveoperational expertise join our board. Steve's experience shepherding ABSGthrough extensive growth provides him with insight that will be of great valueto Thoratec," said Gary F. Burbach, president and chief executive officer ofThoratec. "We are certain Steve will make a meaningful contribution to theboard and the company."
Thoratec Corporation is a world leader in hemodynamic restoration therapy-developing products to treat cardiovascular disease. The company's productline includes the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R)LVAS (Left Ventricular Assist System) with more than 11,000 devices implantedin patients suffering from heart failure. Additionally, its InternationalTechnidyne Corporation (ITC) division supplies blood testing and skin incisionproducts. Thoratec is headquartered in Pleasanton, California. For moreinformation, visit the company's web sites at http://www.thoratec.com orhttp://www.itcmed.com.
Some of the preceding paragraphs, contain forward-looking statementswithin the meaning of Section 27A of the Securities Act of 1933, and Section21E of the Securities Exchange Act of 1934. These statements can be identifiedby the words, "expects," "continues," "projects," "hopes," "believes,""could," and other similar words. Actual results, events or performance coulddiffer materially from these forward-looking statements based on a variety offactors, many of which are beyond Thoratec's control. Therefore, readers arecautioned not to put undue reliance on these statements. Investors arecautioned that all such statements involve risk and uncertainties. Forward-looking statements contained in this press release should be considered inlight of these factors, and those factors discussed from time to time inThoratec's public reports filed with the Securities and Exchange Commission,such as those discussed under the heading, "Risk Factors," in Thoratec's mostrecent annual report on Form 10-K and quarterly report on Form 10-Q. Theseforward-looking statements speak only as of the date hereof. Thoratecundertakes no obligation to publicly release the results of any revisions tothese forward-looking statements that may be made to reflect events orcircumstances after the date hereof, or to reflect the occurrence ofunanticipated events.
SOURCE Thoratec Corporation